Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4763673
Max Phase: Preclinical
Molecular Formula: C19H19F2N3O3
Molecular Weight: 375.38
Molecule Type: Unknown
Associated Items:
ID: ALA4763673
Max Phase: Preclinical
Molecular Formula: C19H19F2N3O3
Molecular Weight: 375.38
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(C)cc2)c(F)c1
Standard InChI: InChI=1S/C19H19F2N3O3/c1-10-3-5-11(6-4-10)23-19(26)24-17-13(9-22-18(17)25)16-14(20)7-12(27-2)8-15(16)21/h3-8,13,17H,9H2,1-2H3,(H,22,25)(H2,23,24,26)/t13-,17-/m0/s1
Standard InChI Key: JDZYRVFPDFZSMG-GUYCJALGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 375.38 | Molecular Weight (Monoisotopic): 375.1394 | AlogP: 2.69 | #Rotatable Bonds: 4 |
Polar Surface Area: 79.46 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.13 | CX Basic pKa: | CX LogP: 2.35 | CX LogD: 2.35 |
Aromatic Rings: 2 | Heavy Atoms: 27 | QED Weighted: 0.77 | Np Likeness Score: -0.77 |
1. Asahina Y,Wurtz NR,Arakawa K,Carson N,Fujii K,Fukuchi K,Garcia R,Hsu MY,Ishiyama J,Ito B,Kick E,Lupisella J,Matsushima S,Ohata K,Ostrowski J,Saito Y,Tsuda K,Villarreal F,Yamada H,Yamaoka T,Wexler R,Gordon D,Kohno Y. (2020) Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure., 63 (17): [PMID:32407089] [10.1021/acs.jmedchem.9b02101] |
2. Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM.. (2021) Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential., 213 [PMID:33486199] [10.1016/j.ejmech.2021.113167] |
Source(1):